Artal Group’s Vera Therapeutics VERA Stock Holding History

Artal Group’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-915,974	Closed	-$33.1M	–	96
2024 Q2	$33.1M	Buy	915,974 +409,955	+81%	+$16.3M	0.84%	16
2024 Q1	$21.8M	Buy	+506,019	New	+$18M	0.56%	25

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group's VERA Position: Q3 2024 in Review

Artal Group sold out of Vera Therapeutics (VERA) in Q3 2024, closing a stake of 915,974 shares — an estimated $33.1M sold.

Artal Group first reported a position in VERA in Q1 2024 and held it in 2 quarters. The position peaked at $33.1M in Q2 2024. 173 funds tracked by Wall St. Rank hold VERA as of Q3 2024.

Artal Group reported no remaining Vera Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 915,974 Vera Therapeutics shares in Q3 2024, an estimated $33.1M.
Artal Group first reported a position in Vera Therapeutics in Q1 2024 and held it in 2 quarters.
Artal Group's Vera Therapeutics position peaked at $33.1M in Q2 2024.
173 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.